文献速递冠心病

DANAMI-2试验16年随访:直接PCI与溶栓治疗ST段抬高型心肌梗死的长期比较

16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction.
PubMed 文献 · Eur Heart J · 2020-01-01

DANAMI-2试验随机分配1572例STEMI患者至直接PCI或溶栓治疗,16年随访显示直接PCI持续降低死亡或心梗再住院复合终点(58.7% vs 62.3%,HR 0.86),心脏死亡率绝对降低4.4%,主要事件平均延迟12.3个月。

要点

  • 直接PCI较溶栓持续降低16年死亡或心梗再住院复合终点风险。
  • 心脏死亡率绝对降低4.4%,全因死亡率无差异。
  • 直接PCI使主要事件平均延迟约12.3个月。

核心结论

  • 直接PCI较溶栓的获益在16年随访时仍持续存在。
  • 直接PCI降低死亡或心梗再住院复合终点及心脏死亡率。

研究设计与样本

  • 随机对照试验,纳入1572例STEMI患者,随机分配至直接PCI或溶栓治疗。
  • 在丹麦24家转诊医院和5家侵入性中心进行,转诊医院患者随机至直接PCI后立即转运至最近侵入性中心。
  • 主要终点为死亡或心梗再住院复合终点,3年后结局通过丹麦健康登记获取。

主要发现

  • 16年时,直接PCI组复合终点发生率58.7%,溶栓组62.3%(HR 0.86,95%CI 0.76-0.98)。
  • 转运行直接PCI亚组复合终点58.7% vs 64.1%(HR 0.82,95%CI 0.71-0.96)。
  • 全因死亡率无差异,但心脏死亡率直接PCI组18.3% vs 溶栓组22.7%(HR 0.78,95%CI 0.63-0.98),绝对降低4.4%。
  • 直接PCI较溶栓平均延迟主要事件12.3个月(95%CI 5.0-19.5)。

临床怎么用

  • 对于STEMI患者,直接PCI应作为优先再灌注策略以改善长期预后。
  • 转诊医院患者可考虑立即转运至侵入性中心行直接PCI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial found that interhospital transport to primary percutaneous coronary intervention (pPCI) was superior to fibrinolysis at the local hospital in patients with ST-segment elevation myocardial infarction (STEMI) at 30 days. The present study investigates the 16-year cardiovascular outcomes. METHODS AND RESULTS: We randomized 1572 STEMI patients to pPCI or fibrinolysis at 24 referral hospitals and 5 invasive centres in Denmark. Patients randomized to pPCI at referral hospitals were immediately transported to the nearest invasive centre. The main endpoint of the current study was a composite of death or rehospitalization for myocardial infarction (MI). Outcome information beyond 3 years was obtained through Danish health registries. After 16 years, pPCI-treated patients had a sustained lower rate of composite endpoint compared to patients treated with fibrinolysis in the overall cohort [58.7% vs. 62.3%; hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.98], and among patients transported for pPCI (58.7% vs. 64.1%; HR 0.82, 95% CI 0.71-0.96). No difference in all-cause mortality was found, but cardiac mortality was reduced by an absolute of 4.4% in favour of pPCI (18.3% vs. 22.7%; HR 0.78, 95% CI 0.63-0.98). pPCI postponed a main event with 12.3 months in average compared to fibrinolysis (95% CI 5.0-19.5). CONCLUSION: The benefit of pPCI over fibrinolysis was maintained at 16-year follow-up. pPCI reduced the composite endpoint of death or rehospitalization for MI, reduced cardiac mortality, and delayed average time to a main event by approximately 1 year.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Thrane PG, Kristensen SD, Olesen KKW, et al. 16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction. Eur Heart J. 2020. PMID: 31504424. doi:10.1093/eurheartj/ehz595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。